History and Future of Treatment for Acute Stage Kawasaki Disease

Area of Science:

• Pediatrics
• Rheumatology
• Cardiology

Background:

• Kawasaki disease is a leading cause of acquired heart disease in children.
• It involves inflammation of small to medium arteries, potentially leading to coronary artery aneurysms.
• The exact cause remains unknown despite extensive research since 1957.

Purpose of the Study:

• To review the historical evolution of acute phase treatments for Kawasaki disease.
• To highlight the shift towards early and aggressive inflammation management.
• To provide an overview of established and emerging therapeutic strategies.

Main Methods:

• This chapter provides a historical review of Kawasaki disease treatments.
• It synthesizes information on various therapeutic interventions.
• Focuses on acute phase management strategies.

Main Results:

• Intravenous immunoglobulin therapy is the established standard treatment.
• Numerous other therapies are being explored, including steroids, infliximab, and plasma exchange.
• The primary goal is to rapidly resolve inflammation and prevent cardiac sequelae.

Conclusions:

• Acute phase treatment for Kawasaki disease has evolved significantly.
• The focus remains on early intervention to minimize coronary artery damage.
• Ongoing research explores diverse treatment options beyond immunoglobulin therapy.